Overall, these findings define a novel ERβ/circAHNAK/FMR1/ADAM17 axis that integrates USP10‐mediated deubiquitination with FMR1‐mediated m6A modification to promote ADAM17 expression and angiogenesis in ccRCC. The gene discussed is ESR2; the disease is nonpapillary renal cell carcinoma.